Retrospective Study on Registry Data to Evaluate the Impact of Ocrelizumab Used in Routine Care in Patients With RRMS
- Conditions
- Multiple Sclerosis
- Registration Number
- NCT04838015
- Lead Sponsor
- University Hospital, Strasbourg, France
- Brief Summary
Multiple Sclerosis (MS) is a chronic, autoimmune, neurodegenerative disease; clinical events are mainly attributed to myelin destruction and inflammatory of the central nervous system.
The diagnosis resides in clinical and radiological criteria according to 2017 McDonald criteria.
Once the diagnosis of MS has been made, treatment should be initiated promptly, in order to delay the onset of severe disability in the long-term, even more ocrelizumab are a treatment of high efficacy.
Ocrelizumab is used as a first-line or second-line treatment in Relapsing Remitting MS (RRMS) It is an anti-CD20 monoclonal antibody that provides rapid depletion of circulating CD20+ B lymphocytes by complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity.
The main objective is the retrospective evaluation of the impact of ocrelizumab on the outcome of MS.
The secondary objective is the search of predictive factors of response to treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 250
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Retrospective study of the impact of ocrelizumab used in patients with multiple sclerosis Files analysed retrospectively from October 01, 2018 to November 31, 2020 will be examined]
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hautepierre Clinical Investigation Center - Strasbourg University Hospitals
🇫🇷Strasbourg, France